Precision radiotherapy for nasopharyngeal carcinoma

Abstract

Nasopharyngeal carcinoma(NPC) occurs frequently in Southern China, and radiotherapy is the main treatment method. At present, intensity-modulated radiotherapy is widely used, which has improved efficacy in patients with NPC and reduced toxicity and side effects. Recently, helical tomography radiotherapy, proton radiotherapy, carbon particle radiotherapy, and other radiotherapy techniques have been used for the clinical treatment of NPC. Individualized nasopharyngeal cancer targets have also been explored. This paper reviews the research progress in radiotherapy techniques and target volume for NPC

Keywords

nasopharyngeal carcinoma / precision radiotherapy / progression / target volume

References

[1] TangLQ, LiCF, LiJ, et al. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2016;108(1):djv291.

[2] ChenYP, ChanA, LeQT, Blanchard P, SunY, MaJ. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80.

[3] TaoHY, ZhanZJ, QiuWZ, et al. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. J Cancer. 2021;12(1):18-27.

[4] PengG, WangT, YangKY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):286-293.

[5] LiaoS, XieY, FengY, et al. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion. J Cancer Res Clin Oncol. 2020;146(2):429-439.

[6] FangFM, ChienCY, TsaiWL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72(2):356-364.

[7] MoonSH, ChoKH, LeeCG, et al. IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : Survival outcome in a Korean multi-institutional retrospective study (KROG 11-06). Strahlenther Onkol. 2016;192(6):377-385.

[8] HeL, XiaoJ, WeiZ, et al. Toxicity and dosimetric analysis of nasopharyngeal carcinoma patients undergoing radiotherapy with IMRT or VMAT: A regional center's experience. Oral Oncol. 2020;109:104978.

[9] ChenBB, HuangSM, XiaoWW, et al. Prospective matched study on comparison of volumetric-modulated arc therapy and intensity-modulated radiotherapy for nasopharyngeal carcinoma: dosimetry, delivery efficiency and outcomes. J Cancer. 2018;9(6):978-986.

[10] HuangTL, TsaiMH, ChuangHC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy. Radiat Oncol. 2020;15(1):84.

[11] LuS, FanH, HuX, et al. Dosimetric Comparison of Helical Tomotherapy, Volume-Modulated Arc Therapy, and Fixed-Field Intensity-Modulated Radiation Therapy in Locally Advanced Nasopharyngeal Carcinoma. Front Oncol. 2021;11:764946.

[12] DuL, ZhangXX, FengLC, et al. Treatment of nasopharyngeal carcinoma using simultaneous modulated accelerated radiation therapy via helical tomotherapy: a phase II study. Radiol Oncol. 2016;50(2):218-225.

[13] WangYC, LiCC, ChienCR. Effectiveness of tomotherapy vs linear accelerator image-guided intensity-modulated radiotherapy for localized pharyngeal cancer treated with definitive concurrent chemoradiotherapy: a Taiwanese population-based propensity score-matched analysis. Br J Radiol. 2018;91(1086):20170947.

[14] HuM, JiangL, CuiX, ZhangJ, YuJ. Proton beam therapy for cancer in the era of precision medicine. J Hematol Oncol. 2018;11(1):136.

[15] YuanTZ, ZhanZJ, QianCN. New frontiers in proton therapy: applications in cancers. Cancer Commun (Lond). 2019;39(1):61.

[16] LewisGD, Holliday EB, Kocak-UzelE, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck. 2016;38(Suppl 1):E1886-E1895.

[17] JiříK, Vladimír V, MichalA, et al. Proton pencil-beam scanning radiotherapy in the treatment of nasopharyngeal cancer: dosimetric parameters and 2-year results. Eur Arch Otorhinolaryngol. 2021;278(3):763-769.

[18] LiX, Kitpanit S, LeeA, et al. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. JAMA Netw Open. 2021;4(6): e2113205.

[19] LeeA, Kitpanit S, ChilovM, LangendijkJA, LuJ, LeeNY. A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer. Int J Part Ther. 2021;8(1):119-130.

[20] DionisiF, CrociS, GiacomelliI, et al. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma. Acta Oncol. 2019;58(9):1238-1245.

[21] DuranteM, Orecchia R, LoefflerJS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. 2017;14(8):483-495.

[22] WangL, HuJ, LiuX, WangW, KongL, Lu JJ. Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison. Cancer Manag Res. 2019;11:7767-7777.

[23] HuJ, HuangQ, GaoJ, et al. Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma. Front Oncol. 2021;11:653050.

[24] HuJ, HuangQ, GaoJ, et al. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer. 2020;126(23):5173-5183.

[25] YangHR, ChenX, LinS, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. Radiother Oncol. 2018;126(1):37-42.

[26] TangLL, HuangCL, ZhangN, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479-490.

[27] MaoYP, WangSX, GaoTS, et al. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023;380:e072133.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.